




RealRate

PHARMACEUTICAL 2017

Bellerophon Therapeutics Inc.
Rank 213 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Bellerophon Therapeutics Inc. Rank 213 of 313

The relative strengths and weaknesses of Bellerophon Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Bellerophon Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 185% points.

The company's Economic Capital Ratio, given in the ranking table, is -371%, being 45% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	26,505
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,495
Liabilities, Non-Current	0
Other Assets	1,798
Other Compr. Net Income	19
Other Expenses	152
Other Liabilities	5,215
Other Net Income	95
Property and Equipment	1,399
Research and Development	16,650
Revenues	0
Selling, General and Administrative Expense	7,107

Output Variable	Value in 1000 USD
Assets	29,702
Liabilities	11,710
Expenses	23,909
Stockholders Equity	17,992
Net Income	-23,814
Comprehensive Net Income	-23,804
Economic Capital Ratio	-371%

